


Claims

1. 3,4-dihydro-*N*-[[1-(3-hydroxybutyl)-4-piperidiny]methyl]-2*H*-
 5 [1,3]oxazino[3,2-*a*]indole-10-carboxamide i.e. the compound of formula (I), or a pharmaceutically acceptable salt thereof:



(I)

10

2. The compound of formula (I) and its pharmaceutically acceptable salts as claimed in claim 1 in pharmaceutically acceptable form.
- 15 3. The compound of formula (I) and its pharmaceutically acceptable salts as claimed in claim 1 or claim 2 in synthetic form.
4. A process for preparing a compound of formula (I) according to claim 1 which comprises reacting 1-(3-(protected)hydroxybutyl)-4-piperidiny] methylamine
 20 with methyl 3,4-dihydro-2*H*-[1,3]oxazino[3,2-*a*]indole-10-carboxylate and subsequently removing the protecting group.
5. A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier.
- 25 6. A compound according to claim 1 for use as an active therapeutic substance.
7. The use of a compound according to claim 1 in the manufacture of a medicament for use as a 5-HT₄ receptor antagonist.
- 30 8. The use according to claim 7 for use as a 5-HT₄ antagonist in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders.
9. A method of treatment of irritable bowel syndrome, gastro-oesophageal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine in
 35 mammals, such as humans, which comprises the administration of an effective

amount of the compound of the formula (I) or a pharmaceutically acceptable salt thereof.